Rituximab and Belimumab for Lupus Nephritis
Public ClinicalTrials.gov record NCT02260934. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Study identification
- NCT ID
- NCT02260934
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Enrollment
- 43 participants
Conditions and interventions
Conditions
Interventions
- Acetaminophen Drug
- Belimumab Biological
- Cyclophosphamide Drug
- Diphenhydramine Drug
- Methylprednisolone Drug
- Prednisone Drug
- Rituximab Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 8, 2015
- Primary completion
- Mar 11, 2018
- Completion
- Feb 7, 2019
- Last update posted
- Nov 30, 2020
2015 – 2019
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama, Birmingham | Birmingham | Alabama | 35294 | — |
| UCLA Medical Center: Division of Rheumatology | Los Angeles | California | 90095 | — |
| University of California, San Francisco | San Francisco | California | 94143 | — |
| University of Colorado Denver: School of Medicine: Division of Rheumatology | Aurora | Colorado | 80045 | — |
| Colorado Kidney Care | Denver | Colorado | 80218 | — |
| Emory University School of Medicine | Atlanta | Georgia | 30303 | — |
| Washington University in St. Louis | St Louis | Missouri | 36110 | — |
| Feinstein Institute, North Shore Hospital | Manhasset | New York | 10030 | — |
| New York University, Langone Medical Center | New York | New York | 10016 | — |
| Weill Cornell Medical College: Hospital for Special Surgery - | New York | New York | 10021 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| University of North Carolina School of Medicine: | Chapel Hill | North Carolina | 27599 | — |
| Ohio State University Wexner Medical Center: | Columbus | Ohio | 43213 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| University of Texas Southwestern | Dallas | Texas | 75390 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02260934, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 30, 2020 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02260934 live on ClinicalTrials.gov.